Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday.
美国股市大多走低，道琼斯指数周五下跌超过20点。
Shares of Ross Stores, Inc. (NASDAQ:ROST) surged during Friday's session as the company reported upbeat results for its third quarter and raised FY23 earnings guidance.
罗斯百货公司（纳斯达克股票代码：ROST）的股价在周五的交易中飙升，原因是该公司公布了第三季度乐观的业绩，并上调了2023财年的收益预期。
Ross Stores reported quarterly earnings of $1.33 per share, surpassing estimates of $1.21, representing a 33% increase over earnings of $1.00 per share from the same period last year. Revenue clocked in at $4.92 billion, above the analyst consensus estimate of $4.82 billion, according to data from Benzinga Pro.
罗斯百货公布的季度每股收益为1.33美元，超过了预期的1.21美元，比去年同期的每股收益1.00美元增长了33％。Benzinga Pro的数据显示，收入为49.2亿美元，高于分析师普遍估计的48.2亿美元。
The company raised its full-year 2023 earnings per share outlook from between $5.15 and $5.26 to between $5.30 and $5.36.
该公司将其2023年全年每股收益展望从5.15美元至5.26美元之间上调至5.30美元至5.36美元之间。
Ross Stores shares climbed 8.8% to $130.67 on Friday.
周五，罗斯百货股价上涨8.8％，至130.67美元。
Here are some big stocks recording gains in today's session.
以下是一些在今天交易日上涨的大型股票。
- The Gap, Inc. (NYSE:GPS) shares jumped 26.9% to $17.35 after the company reported better-than-expected financial results for the third quarter on Thursday.
- Twist Bioscience Corporation (NASDAQ:TWST) surged 20.2% to $22.93 following strong quarterly results.
- Qifu Technology, Inc. (NASDAQ:QFIN) shares rose 14% to $17.66 following third-quarter results.
- GDEV Inc. (NASDAQ:GDEV) climbed 13.2% to $3.00.
- VNET Group, Inc. (NASDAQ:VNET) gained 13% to $2.95.
- Caribou Biosciences, Inc. (NASDAQ:CRBU) surged 12.4% to $5.32.
- Icosavax, Inc. (NASDAQ:ICVX) rose 11.2% to $10.36. Guggenheim initiated coverage on Icosavax with a Buy rating and announced a price target of $28.
- Globant S.A. (NYSE:GLOB) jumped 12.4% to $205.73 following upbeat third-quarter results.
- Brookdale Senior Living Inc. (NYSE:BKD) rose 11.2% to $5.03. RBC Capital upgraded Brookdale Senior Living from Sector Perform to Outperform and raised the price target from $7 to $9.
- Tenet Healthcare Corporation (NYSE:THC) gained 11% to $64.60 after it inked a deal with Novant Health to sell three hospitals and related operations in South Carolina for around $2.4 billion in cash.
- CRISPR Therapeutics AG (NASDAQ:CRSP) gained 8.4% to $64.50. CRISPR Therapeutics recently announced regulatory authorization of the first CRISPR/Cas9 gene-edited therapy.
- Manchester United plc (NYSE:MANU) gained 7.4% to $19.79 following a report suggesting Jim Ratcliffe's Ineos Sports is in talks to buy a 25% stake in the club for $33 per share.
- Abercrombie & Fitch Co. (NYSE:ANF) gained 7.4% to $74.10.
- The Buckle, Inc. (NYSE:BKE) rose 7.3% to $37.50 following upbeat earnings.
- Gap, Inc.（纽约证券交易所代码：GPS）周四公布的第三季度财务业绩好于预期后，股价上涨26.9％，至17.35美元。
- 继强劲的季度业绩之后，Twist生物科学公司（纳斯达克股票代码：TWST）飙升20.2％，至22.93美元。
- 第三季度业绩公布后，启富科技股份有限公司（纳斯达克股票代码：QFIN）股价上涨14％，至17.66美元。
- GDEV Inc.（纳斯达克股票代码：GDEV）上涨13.2％，至3.00美元。
- VNET集团有限公司（纳斯达克股票代码：VNET）上涨13％，至2.95美元。
- Caribou Biosciences, Inc.（纳斯达克股票代码：CRBU）飙升12.4％，至5.32美元。
- Icosavax, Inc.（纳斯达克股票代码：ICVX）上涨11.2％，至10.36美元。古根海姆以买入评级开始对Icosavax进行报道，并宣布目标股价为28美元。
- 继第三季度业绩乐观之后，Globant S.A.（纽约证券交易所代码：GLOB）上涨12.4％，至205.73美元。
- 布鲁克代尔老年生活公司（纽约证券交易所代码：BKD）上涨11.2％，至5.03美元。加拿大皇家银行资本将Brookdale Senior Living从行业表现上调至跑赢大盘，并将目标股价从7美元上调至9美元。
- Tenet Healthcare Corporation（纽约证券交易所代码：THC）上涨11％，至64.60美元，此前该公司与Novant Health签署了一项协议，以约24亿美元的现金出售南卡罗来纳州的三家医院和相关业务。
- CRISPR Therapeutics AG（纳斯达克股票代码：CRSP）上涨8.4％，至64.50美元。CRISPR Therapeutics最近宣布了首款CRISPR/Cas9基因编辑疗法的监管授权。
- 曼联集团（纽约证券交易所代码：MANU）上涨7.4％，至19.79美元，此前有报道称吉姆·拉特克利夫旗下的Ineos Sports正在谈判以每股33美元的价格收购该俱乐部25％的股份。
- Abercrombie & Fitch Co.纽约证券交易所代码：ANF）上涨7.4％，至74.10美元。
- 在收益乐观之后，Buckle, Inc.（纽约证券交易所代码：BKE）上涨7.3％，至37.50美元。
Now Read This: Jim Cramer Has A 'Problem' With This Fintech Giant: 'I Like The Mastercards And The Visas Now'
现在读这个： 吉姆·克莱默对这家金融科技巨头有一个 “问题”：“我现在喜欢万事达卡和签证”